Wed, Jul 9, 2014, 8:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

  • bluecheese4u bluecheese4u Oct 25, 2012 9:11 AM Flag

    Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter

    Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter

    -- Non-GAAP Diluted EPS Rises 19%; GAAP Diluted EPS Up 17% --

    -- Long-lasting Factor IX Hemophilia Candidate Reaches Primary Safety and Efficacy Endpoints in Phase 3 Trial --

    -- Focus Remains on Commercial Execution, Investing in Future Success, Preparing for Upcoming Milestones --

    WESTON, Mass.--(BUSINESS WIRE)--Oct. 25, 2012-- Biogen Idec Inc. (NASDAQ: BIIB) today announced third quarter 2012 financial results, delivering revenue growth of 6 percent to $1.4 billion and non-GAAP diluted Earnings Per Share (EPS) growth of 19 percent.

    Third Quarter 2012 Highlights:
    AVONEX® (interferon beta-1a) revenues increased 8 percent year-over-year to $736 million. TYSABRI® (natalizumab) revenues were $275 million, a decrease of 1 percent, compared to the third quarter of 2011. RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $288 million for the quarter, an increase of 8 percent year-over-year.
    Global in-market sales of TYSABRI in the third quarter of 2012 were $404 million, an increase of 3 percent over the third quarter of 2011. The total was comprised of $230 million in United States sales and $173 million in sales outside the U.S.
    During the third quarter, Biogen Idec recognized a gain of $32 million in relation to the sale of our royalty and other rights related to BENLYSTA® (belimumab) to a DRI Capital managed fund (DRI). Under the terms of the agreement, Biogen Idec will receive a multiple on certain royalties payable to DRI for the period covering October 2011 through September 2014. The initial amount recognized covers the royalty period from October 1, 2011 through June 30, 2012.
    Third quarter 2012 GAAP diluted EPS was $1.67, an increase of 17 percent as compared to the third quarter of 2011. GAAP net income attributable to Biogen Idec for the quarter was $398 million, an increase of 13 percent as compared to the third quarter of 2011.
    Non-GAAP diluted EPS for the third quarter of 2012 was $1.91, an increase of 19 percent as compared to the third quarter of 2011. Non-GAAP net income attributable to Biogen Idec for the third quarter of 2012 was $455 million, an increase of 15 percent as compared to the third quarter of 2011. A reconciliation of our GAAP to non-GAAP results is included in Table 3 within this press release.

    As of September 30, 2012, Biogen Idec had cash, cash equivalents and marketable securities of approximately $3.3 billion.

    “Through the first three quarters of 2012, Biogen Idec is on track to accomplish what we set out to do at the beginning of the year,” said George A. Scangos, Ph.D., chief executive officer. “We have enhanced our leadership position in the multiple sclerosis market with strong results from AVONEX and TYSABRI; we have advanced our late-stage pipeline, with positive results from the registrational study for factor IX in hemophilia B; and we continue preparations for the potential launch of BG-12 next year. We look forward to data readouts for factor VIII in hemophilia A soon, followed by dexpramipexole in ALS and PEGylated interferon in relapsing MS in the coming months. Our hard work is reflected in this quarter’s results.”

    TYSABRI Patient Growth

    Based upon data available to us through the TOUCH®prescribing program and other third party sources, as of the end of September 2012, we estimate that approximately 71,100 patients are on commercial and clinical TYSABRI therapy worldwide, and that cumulatively, approximately 108,300 patients have been treated with TYSABRI in the post-marketing setting.

    Other Products and Royalty Revenues

    Revenues from other products in the third quarter of 2012 were $28 million, compared to $17 million in the third quarter of 2011.

    Table 4 provides individual product revenues.

    Royalty revenues were $47 million in the third quarter of 2012, compared to $52 million in the third quarter of 2011.

    For the third quarter of 2012, corporate partner revenues were $12 million, compared to $16 million in the third quarter of 2011.

    Updated 2012 Financial Guidance

    Biogen Idec also updated its full year 2012 financial guidance. This guidance consists of the following components:
    Revenue growth is expected to be in the mid to high-single digits versus 2011.
    Cost of Sales is expected to be approximately 9 percent to 10 percent of total revenue.
    R&D expense is expected to be approximately 24 percent to 25 percent of total revenue. R&D expense is inclusive of approximately $20 to $30 million of a potential upfront payment in the fourth quarter earmarked for a discovery collaboration which we are in the process of negotiating.
    SG&A expense is expected to be approximately 22 percent to 23 percent of total revenue.
    Tax expense is expected to be approximately 23 percent to 25 percent of pretax income.
    Non-GAAP diluted EPS is expected to be between $6.40 and $6.50.
    GAAP diluted EPS is expected to be between $5.63 and $5.73.
    Capital expenditures are expected to be in the range of $230 to $250 million.

    Biogen Idec may incur charges, realize gains or experience other events in 2012 that could cause actual results to vary from this guidance.

    Recent Events
    On October 18, Biogen Idec announced the U.S. Food and Drug Administration (FDA) has extended the initial PDUFA date for its review of the New Drug Application (NDA) for the marketing approval of BG-12 (dimethyl fumarate), the company’s oral therapeutic candidate for the treatment of multiple sclerosis (MS). The three month extension is a standard extension period. The FDA has indicated that the extension of the PDUFA date is needed to allow additional time for review of the application. The agency did not ask for additional studies.
    On October 10, Biogen Idec presented extensive data from the company’s leading MS franchise during the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France. Fifty-three poster and platform presentations further showcased Biogen Idec’s commitment to advancing the treatment of MS and improving the lives of people living with the disease around the world. Approved and investigational therapies in Biogen Idec’s MS franchise presented at the conference included BG-12, daclizumab-HYP, anti-LINGO, TYSABRI, AVONEX and FAMPYRA® (prolonged-release fampridine tablets).

    Third Quarter Events
    On September 26, Biogen Idec and Swedish Orphan Biovitrum (Sobi) announced positive top-line results from a Phase 3 study investigating long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B. The primary efficacy and safety objectives were met and Biogen Idec plans to submit a Biologics License Application to the FDA by the first quarter of 2013.
    On September 19, Biogen Idec announced that the September 20, 2012 issue of the New England Journal of Medicine (NEJM) published detailed results from two pivotal clinical trials that evaluated oral BG-12 for the treatment of MS. Results of the Phase 3 DEFINE and CONFIRM studies support BG-12’s potential as a new oral option for MS treatment.

    Conference Call and Webcast

    The company's earnings conference call for the third quarter will be broadcast via the internet at 8:00 a.m. ET on October 25, 2012,

    biogenidec

 
BIIB
320.14+2.55(+0.80%)Jul 9 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.